The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A Randomized Trial of the Efficacy and Tolerability of the COX-2 Inhibitor Rofecoxib vs Ibuprofen in Patients With Osteoarthritis
Abstract
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). It is not known whether a specific inhibitor of COX-2 will provide efficacy in osteoarthritis (OA) comparable with NSAIDs. Therefore, we compared the efficacy and safety of the rofecoxib, which specifically inhibits COX-2, with those of the NSAID ibuprofen in patients with OA. OBJECTIVE: To compare the clinical efficacy and tolerability of rofecoxib (12.5 and 25 mg once daily) with ibuprofen (800 mg 3 times daily). METHODS: A randomized, double-blind trial of 809 adults with OA was conducted. Patients with OA in whom the knee or hip was the primary source of pain were randomized to 1 of 4 treatment groups on demonstration of disease activity: placebo; rofecoxib, 12.5 or 25 mg once daily; or ibuprofen, 800 mg 3 times daily. Clinical efficacy and safety were monitored during a 6-week treatment period. RESULTS: Both doses of rofecoxib demonstrated efficacy clinically comparable with ibuprofen as assessed by 3 primary end points (pain walking on a flat surface [Western Ontario and McMaster Universities Osteoarthritis Index], patient global assessment of response to therapy, and investigator global assessment of disease status) according to predefined comparability criteria. Both rofecoxib doses and the ibuprofen dose provided significantly (P<.001) greater efficacy than placebo on all primary end points. Results from secondary end points were consistent with those of the primary end points. All treatments were well tolerated; the overall incidence rates of clinical adverse experiences were not significantly different (P>.05) among the treatment groups. CONCLUSION: Rofecoxib was well tolerated and provided clinical efficacy comparable with a high dose of the NSAID ibuprofen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98774-0 · Cited by 1,789
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient Mice
Lim, H., Paria, B. C., Das, S. K., Dinchuk, J. E., Langenbach, R., Trzaskos, J. M., & Dey, S. K. (1997) · Cell · doi:10.1016/s0092-8674(00)80402-x · Cited by 1,430
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310 · cited 1×
“The therapeutic effects of NSAIDs may be attributable to COX-2 inhibition.(21,28,29) Therefore, agents that specifically inhibit COX-2 are being evaluated to determine whether they have efficacy equal to NSAIDs with an improved GI tract safety profile.”
BackgroundMeade, E. A., Smith, W. L., & DeWitt, D. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53294-4 · Cited by 1,256
Gabriel, S. E., Jaakkimainen, L., & Bombardier, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-10-787 · Cited by 1,237
Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., & Worley, P. F. (1993) · Neuron · doi:10.1016/0896-6273(93)90192-t · Cited by 1,226
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O'Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 821
Prostaglandin endoperoxide synthase: regulation of enzyme expression
DeWitt, D. L. (1991) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(91)90032-d · Cited by 637
Kaufmann, W. E., Worley, P. F., Pegg, J., Bremer, M., & Isakson, P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2317 · Cited by 593
Laneuville, O., Breuer, D. K., Dewitt, D. L., Hla, T., Funk, C. D., & Smith, W. L. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23861-7 · Cited by 472
Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., & O'Neill, G. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690211 · Cited by 462
Komhoff, M., Grone, H. J., Klein, T., Seyberth, H. W., & Nusing, R. M. (1997) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1997.272.4.f460 · Cited by 365
EHRICH, E., DALLOB, A., DELEPELEIRE, I., VANHECKEN, A., RIENDEAU, D., YUAN, W., PORRAS, A., WITTREICH, J., SEIBOLD, J., & DESCHEPPER, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70113-x · Cited by 322
Chan, C. C., Boyce, S., Brideau, C., Ford-Hutchinson, A. W., Gordon, R., Guay, D., Hill, R. G., Li, C. S., Mancini, J., & Penneton, M. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10713-1 · Cited by 313
Role of inducible cyclooxygenase (COX-2) in inflammation.
Seibert, K., & Masferrer, J. L. (1994) · PubMed · Cited by 270
Sirois, J., Simmons, D. L., & Richards, J. S. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49951-1 · Cited by 255
O'Neill, G. P., Mancini, J. A., Kargman, S., Yergey, J., Kwan, M. Y., Falgueyret, J. P., Abramovitz, M., Kennedy, B. P., Ouellet, M., & Cromlish, W. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09920-1 · Cited by 181
Ehrich, E. W., Schnitzer, T. J., McIlwain, H. H., Levy, R. M., Wolfe, F., Weisman, M. H., Zeng, Q., Morrison, B. W., Bolognese, J., Seidenberg, B. C., et al. (1999) · PubMed · Cited by 146
Wu, K. K., Sanduja, R., Tsai, A., Ferhanoğlu, B., & Loose, D. S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2384 · Cited by 146
Bellamy, N., Carette, S., Ford, P. M., Kean, W. F., LeRICHE, N. G. H., Lussier, A., Wells, G. A., & Campbell, J. (1992) · PubMed · Cited by 144
Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis.
Robertson, R. P. (1998) · Diabetes · doi:10.2337/diabetes.47.9.1379 · Cited by 117
Cyclooxygenase‐2 and its regulation in inflammation
Bakhle, Y. S., & Botting, R. M. (1996) · Mediators of Inflammation · doi:10.1155/s0962935196000452 · Cited by 112
Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells
Kargman, S., Wong, E., Greig, G. M., Falgueyret, J., Cromlish, W. A., Ethier, D., Yergey, J. A., Riendeau, D., Evans, J. F., Kennedy, B. P., et al. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00462-5 · Cited by 104
Lyons-Giordano, B., Pratta, M. A., Galbraith, W., Davis, G. L., & Arner, E. C. (1993) · Experimental Cell Research · doi:10.1006/excr.1993.1120 · Cited by 103
Akarasereenont, P., Mitchell, J. A., Appleton, I., Thiemermann, C., & Vane, J. R. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb17169.x · Cited by 93
Berg, J., Christoph, T., Widerna, M., & Bodenteich, A. (1997) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(97)00016-6 · Cited by 43
Vadas, P., Stefanski, E., Wloch, M., Grouix, B., van den BOSCH, H., & Kennedy, B. P. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.t01-1-00557.x · Cited by 41
(1988) · PubMed
Cited by
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Self-citationRecommendations for the medical management of osteoarthritis of the hip and knee: 2000 update
(2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200009)43:9<1905::aid-anr1>3.0.co;2-p · Cited by 1,875
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Metadata
- Authors
- Day, R.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-06-26
- Volume
- 160
- Issue
- 12
- Pages
- 1781
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2123366546
- Cited by
- 264
- References
- 32
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.